Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) issued its earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01, Zacks reports. The firm had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the business earned ($0.30) EPS. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Stock Performance

KPTI stock remained flat at $0.88 during midday trading on Thursday. The company had a trading volume of 1,306,431 shares, compared to its average volume of 1,269,642. The stock’s fifty day moving average is $0.81 and its 200-day moving average is $0.91. The stock has a market capitalization of $109.99 million, a PE ratio of -0.76 and a beta of 0.16. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KPTI. Piper Sandler lifted their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).